Importance of tailored non-clinical safety testing of novel antimalarial drugs: Industry best-practice.

Autor: Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: philip.hewitt@merckgroup.com., Hartmann A; Preclinical Safety, Novartis Pharma AG, Basel, Switzerland., Tornesi B; Non-Clinical Pharmacology & Toxicology, Medicines for Malaria Venture, Geneva, Switzerland., Ferry-Martin S; Nonclinical Drug Safety, Merck Research Laboratories, Merck Sharp & Dohme, Clermont-Ferrand, France., Valentin JP; Early Clinical Development & Translational Science, Non-Clinical Safety Evaluation, UCB Pharma, Braine L'Alleud, Belgium., Desert P; Nonclinical Safety, Sanofi, Marcy l'Etoile, France., Gresham S; Non-Clinical Safety, GSK R&D, Stevenage, UK., Demarta-Gatsi C; Global Health R&D of Merck Healthcare, Ares Trading S.A., (a subsidiary of Merck KGaA, Darmstadt, Germany), Switzerland., Venishetty VK; Pharmacokinetic Sciences, Novartis Pharma AG, Hyderabad, India., Kolly C; Preclinical Safety, Novartis Pharma AG, Basel, Switzerland.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 Nov 06; Vol. 154, pp. 105736. Date of Electronic Publication: 2024 Nov 06.

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model.

Autor: Demarta-Gatsi C; Medicines for Malaria Venture, Geneva, Switzerland., Andenmatten N; Medicines for Malaria Venture, Geneva, Switzerland., Jiménez-Díaz MB; The Art of Discovery, Derio, Basque Country, Spain., Gobeau N; Medicines for Malaria Venture, Geneva, Switzerland., Cherkaoui-Rabti MH; Medicines for Malaria Venture, Geneva, Switzerland., Fuchs A; Medicines for Malaria Venture, Geneva, Switzerland., Díaz P; The Art of Discovery, Derio, Basque Country, Spain., Berja S; The Art of Discovery, Derio, Basque Country, Spain., Sánchez R; The Art of Discovery, Derio, Basque Country, Spain., Gómez H; The Art of Discovery, Derio, Basque Country, Spain., Ruiz E; The Art of Discovery, Derio, Basque Country, Spain., Sainz P; The Art of Discovery, Derio, Basque Country, Spain., Salazar E; The Art of Discovery, Derio, Basque Country, Spain., Gil-Merino R; The Art of Discovery, Derio, Basque Country, Spain., Mendoza LM; The Art of Discovery, Derio, Basque Country, Spain., Eguizabal C; Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.; Basque Centre for Blood Transfusion and Human Tissues, Galdakao, Bizkaia, Spain., Leroy D; Medicines for Malaria Venture, Geneva, Switzerland., Moehrle JJ; Medicines for Malaria Venture, Geneva, Switzerland., Tornesi B; Medicines for Malaria Venture, Geneva, Switzerland., Angulo-Barturen I; The Art of Discovery, Derio, Basque Country, Spain.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Jun 15; Vol. 67 (6), pp. e0157422. Date of Electronic Publication: 2023 May 03.

Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.

Autor: Pontikos MA; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States., Leija C; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States., Zhao Z; Children's Medical Center Research Institute, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, United States., Wang X; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States., Kilgore J; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States., Tornesi B; Medicines for Malaria Venture, 1215 Geneva, Switzerland., Adenmatten N; Medicines for Malaria Venture, 1215 Geneva, Switzerland., Phillips MA; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States. Electronic address: Margaret.Phillips@UTSouthwestern.edu., Williams NS; Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9135, United States. Electronic address: Noelle.Williams@UTSouthwestern.edu.

Publikováno v: Biochemical pharmacology [Biochem Pharmacol] 2022 Oct; Vol. 204, pp. 115237. Date of Electronic Publication: 2022 Aug 31.

Re-orienting anti-malarial drug development to better serve pregnant women.

Autor: El Gaaloul M; Medicines for Malaria Venture, Geneva, Switzerland., Tornesi B; Medicines for Malaria Venture, Geneva, Switzerland., Lebus F; FSG, Rue de Lausanne 82, Geneva, Switzerland., Reddy D; Medicines for Malaria Venture, Geneva, Switzerland., Kaszubska W; Medicines for Malaria Venture, Geneva, Switzerland. kaszubskaw@mmv.org.

Publikováno v: Malaria journal [Malar J] 2022 Apr 12; Vol. 21 (1), pp. 121. Date of Electronic Publication: 2022 Apr 12.

Birth Control in Clinical Trials

Autor: Stewart, J., Breslin, W. J., Beyer, B. K., Chadwick, K., De Schaepdrijver, L., Desai, M., Enright, B., Foster, W., Hui, J. Y., Moffat, G. J., Tornesi, B., Van Malderen, K., Wiesner, L., Chen, C. L.

Publikováno v: Therapeutic Innovation & Regulatory Science

The Health and Environmental Sciences Institute (HESI) Developmental and Reproductive Toxicology Technical Committee sponsored a pharmaceutical industry survey on current industry practices for contraception use during clinical trials. The objectives

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::77d7be0c230f0b979aaa6a5db2ed7f94
http://europepmc.org/articles/PMC4766962